A plain language summary of how lefamulin alone can be used to treat pneumonia caught outside of the hospital due to common bacterial causes, including drug-resistant bacteria.
Antibiotic
antibiotic resistance
bacterial pneumonia
infection
lay summary
lefamulin
plain language summary
pleuromutilin
pneumonia
Journal
Future microbiology
ISSN: 1746-0921
Titre abrégé: Future Microbiol
Pays: England
ID NLM: 101278120
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
pubmed:
15
3
2022
medline:
5
4
2022
entrez:
14
3
2022
Statut:
ppublish
Résumé
Bacterial pneumonia is an infection of the lung caused by bacteria that is potentially deadly, costly, and affects millions of people worldwide every year. Treatment is becoming more challenging-many current treatments no longer work well because some strains of bacteria that cause pneumonia have become resistant to current antibiotics. Many of the antibiotics that do still work have undesirable side effects. Therefore, new antibiotics that work differently are needed to treat bacterial pneumonia. Lefamulin (brand name, Xenleta After the studies were completed, the researchers looked back at what kinds of bacteria were identified from the study participants. Lefamulin worked well to kill bacteria and to improve CABP symptoms for most kinds of infecting bacteria, including bacteria resistant to many current antibiotics. These results suggest that lefamulin, by itself, provides a much-needed treatment option for CABP that covers most of the key bacteria causing this infection.
Identifiants
pubmed: 35285291
doi: 10.2217/fmb-2021-0276
pmc: PMC9096602
doi:
Substances chimiques
Anti-Bacterial Agents
0
Diterpenes
0
Polycyclic Compounds
0
Thioglycolates
0
lefamulin
21904A5386
Types de publication
Journal Article
Review
Research Support, U.S. Gov't, P.H.S.
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
397-410Commentaires et corrections
Type : CommentOn
Type : CommentOn